Parexel acquired Vitrana, an AI pharmacovigilance technology developer, to automate high-volume drug safety workflows and reduce manual bottlenecks in clinical trials. The CRO said the platform targets operationally intensive tasks including case intake, data extraction, entity mapping, narrative generation, and reconciliation. Parexel positioned the move as a way to improve adverse event processing speed and consistency as regulators increase the volume and complexity of global safety reporting requirements. The company also cited performance metrics from Vitrana’s deployment across more than 30 customers, including reported reductions in case processing time and manual reconciliation. Financial terms were not disclosed, but the acquisition reinforces how services firms are bundling AI tools into patient safety operations.